| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 07, 2022 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,188 | -- | 79,686 | |
| Jul 07, 2022 | EVP and CFO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 1,509 | $20.54 | 78,177 | |
| Jul 07, 2022 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,357 | -- | -- | |
| Oct 20, 2021 | SVP Global Operations and R&D | Form 4 | Open market or private sale of non-derivative or derivative security | 3,494 | $27.97 | 26,387 | |
| Aug 17, 2021 | SVP/GM, Vascular Access | Form 4 | Other acquisition or disposition | 8,777 | -- | 8,777 | |
| Aug 17, 2021 | Director, President and CEO | Form 4 | Other acquisition or disposition | 52,378 | -- | 52,378 | |
| Aug 17, 2021 | SVP Global Operations and R&D | Form 4 | Other acquisition or disposition | 8,116 | -- | 8,116 | |
| Aug 17, 2021 | EVP and CFO | Form 4 | Other acquisition or disposition | 14,817 | -- | 14,817 | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,395 | -- | 29,056 | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 702 | $27.29 | 28,354 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.